Literature DB >> 2949114

Pharmacology of antiandrogens.

F Neumann, M Töpert.   

Abstract

Principally, antiandrogens affect all androgen-dependent organs and functions as for instance accessory sexual glands, spermatogenesis, skin and skin appendages, libido and potency, male sexual differentiation, longitudinal bone growth and bone maturation. Pharmacologically, it is important to distinguish between the steroidal antiandrogens of the cyproterone acetate type and the nonsteroidal pure antiandrogens (flutamide, anandrone). For the clinical use of cyproterone acetate and similar antiandrogens in both men and women the three main properties are important: Cyproterone acetate is antiandrogenic, it is a quite potent progestogen and it is antigonadotrophic. Based on pharmacological and biochemical backgrounds cyproterone acetate is used in the following indications: Androgen mediated disorders of the skin such as acne, seborrhoea, hirsutism, alopecia, advanced prostatic carcinoma, precocious puberty and male hypersexuality. In order to avoid undesired systemic side effects local application of antiandrogens, e.g. of cyproterone acetate, has been tried several times. All these attempts have failed probably because insufficient concentration of the antiandrogen at the pilo sebaceous unit. 17 alpha-propylmesterolone is active when given topically (hamster ear model) and has no systemic antiandrogenic effects. This antiandrogen is highly lipophilic and does penetrate preferentially through the hair follicle as has been shown by autoradiography.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2949114     DOI: 10.1016/0022-4731(86)90320-1

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  9 in total

Review 1.  How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

Authors:  E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 2.  Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Authors:  C Mahler; J Verhelst; L Denis
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

3.  Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience.

Authors:  Thomas Samoyeau; Marc Zanello; Alexandre Roux; Joseph Benzakoun; Henri Malaize; Sophie Peeters; Gilles Zah-Bi; Myriam Edjlali; Arnault Tauziede-Espariat; Edouard Dezamis; Eduardo Parraga; Fabrice Chrétien; Pascale Varlet; Geneviève Plu-Bureau; Catherine Oppenheim; Johan Pallud
Journal:  J Neurooncol       Date:  2021-01-15       Impact factor: 4.130

4.  Androgen receptor-blocking agents: potential role in pancreatic cancer.

Authors:  B A Greenway
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

5.  Meningioma in patients exposed to progestin drugs: results from a real-life screening program.

Authors:  Catherine Oppenheim; Joseph Benzakoun; Thomas Samoyeau; Corentin Provost; Alexandre Roux; Laurence Legrand; Edouard Dezamis; Geneviève Plu-Bureau; Johan Pallud
Journal:  J Neurooncol       Date:  2022-09-06       Impact factor: 4.506

Review 6.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

7.  Process development for the production of 15β-hydroxycyproterone acetate using Bacillus megaterium expressing CYP106A2 as whole-cell biocatalyst.

Authors:  Flora M Kiss; Marie T Lundemo; Josef Zapp; John M Woodley; Rita Bernhardt
Journal:  Microb Cell Fact       Date:  2015-03-05       Impact factor: 5.328

8.  Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques.

Authors:  H J Pan; G Wilding; H Uno; S Inui; L Goldsmith; E Messing; C Chang
Journal:  Endocrine       Date:  1998-08       Impact factor: 3.925

9.  Transcription factors involved in prostate gland adaptation to androgen deprivation.

Authors:  Rafaela Rosa-Ribeiro; Umar Nishan; Ramon Oliveira Vidal; Guilherme Oliveira Barbosa; Leonardo Oliveira Reis; Carlos Lenz Cesar; Hernandes F Carvalho
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.